However, there are groups of ERBB2+ breast cancer, lung cancer, esophageal cancers, and gastrointestinal cancers that are resistant to trastuzumab and tyrosine kinase inhibitors (Derakhshani et al, 2020; Bose and Ma, 2021; Hanker et al 2021; Zhang, 2021; Li et al, 2022). This evidence concerns the gene ERBB2 and breast carcinoma.